Insmed (NASDAQ:INSM) CEO Sells $1,746,290.78 in Stock

Insmed, Inc. (NASDAQ:INSM) CEO William Lewis sold 10,699 shares of the business’s stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $163.22, for a total transaction of $1,746,290.78. Following the transaction, the chief executive officer owned 301,185 shares of the company’s stock, valued at approximately $49,159,415.70. This represents a 3.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

William Lewis also recently made the following trade(s):

• On Thursday, March 19th, William Lewis sold 10,699 shares of Insmed stock. The shares were sold at an average price of $143.52, for a total transaction of $1,535,520.48.
• On Thursday, March 5th, William Lewis sold 10,699 shares of Insmed stock. The shares were sold at an average price of $146.03, for a total transaction of $1,562,374.97.
• On Thursday, February 19th, William Lewis sold 10,699 shares of Insmed stock. The shares were sold at an average price of $150.97, for a total transaction of $1,615,228.03.
• On Monday, February 9th, William Lewis sold 13,396 shares of Insmed stock. The shares were sold at an average price of $147.79, for a total transaction of $1,979,794.84.
• On Tuesday, February 3rd, William Lewis sold 3,009 shares of Insmed stock. The stock was sold at an average price of $156.34, for a total transaction of $470,427.06.
• On Tuesday, January 20th, William Lewis sold 10,699 shares of Insmed stock. The stock was sold at an average price of $158.93, for a total transaction of $1,700,392.07.
• On Monday, January 12th, William Lewis sold 19,215 shares of Insmed stock. The stock was sold at an average price of $169.00, for a total transaction of $3,247,335.00.
• On Thursday, January 8th, William Lewis sold 3,223 shares of Insmed stock. The stock was sold at an average price of $174.17, for a total transaction of $561,349.91.

Insmed Price Performance

Shares of NASDAQ:INSM traded down $2.85 during trading on Wednesday, hitting $160.18. 3,355,973 shares of the company were exchanged, compared to its average volume of 2,538,183. The business’s 50 day moving average is $150.39 and its 200-day moving average is $167.08. The company has a market capitalization of $34.57 billion, a P/E ratio of -24.99 and a beta of 1.10. The company has a quick ratio of 3.54, a current ratio of 3.83 and a debt-to-equity ratio of 0.76. Insmed, Inc. has a 1-year low of $60.40 and a 1-year high of $212.75.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.07) by ($0.47). The company had revenue of $263.84 million for the quarter, compared to analyst estimates of $263.97 million. Insmed had a negative return on equity of 168.36% and a negative net margin of 210.54%.The firm’s quarterly revenue was up 152.6% on a year-over-year basis. During the same quarter last year, the company posted ($1.32) earnings per share. Equities analysts forecast that Insmed, Inc. will post -4.56 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on INSM shares. Mizuho upped their price target on shares of Insmed from $204.00 to $206.00 and gave the stock an “outperform” rating in a report on Wednesday, March 25th. Leerink Partners upped their price target on shares of Insmed from $210.00 to $215.00 and gave the stock an “outperform” rating in a report on Tuesday, March 24th. The Goldman Sachs Group upped their price target on shares of Insmed from $225.00 to $258.00 and gave the stock a “buy” rating in a report on Monday, December 15th. Morgan Stanley upgraded shares of Insmed from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $166.00 to $212.00 in a report on Monday, March 30th. Finally, Roth Mkm upgraded Insmed to a “strong-buy” rating in a report on Friday, January 23rd. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Insmed presently has an average rating of “Buy” and a consensus price target of $212.67.

Institutional Trading of Insmed

Institutional investors and hedge funds have recently bought and sold shares of the stock. CIBC Private Wealth Group LLC increased its holdings in Insmed by 42.1% in the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 53 shares during the period. CoreCap Advisors LLC acquired a new stake in Insmed in the fourth quarter valued at $27,000. Stone House Investment Management LLC acquired a new stake in Insmed in the third quarter valued at $29,000. SBI Securities Co. Ltd. increased its holdings in Insmed by 404.9% in the third quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 166 shares during the period. Finally, GraniteShares Advisors LLC acquired a new stake in Insmed in the fourth quarter valued at $30,000.

Key Headlines Impacting Insmed

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: Company says safety profile for brensocatib in the Phase 2b CEDAR study was consistent with prior trials and no new safety signals were identified, which limits downside from unexpected safety issues and preserves value for remaining programs. Insmed Provides Clinical Update on Phase 2b CEDAR Study
• Neutral Sentiment: Market commentators noted the brensocatib miss was largely anticipated by some investors/analysts, which may have tempered the reaction versus a surprise blow-up. Novo underprices Lilly with higher-dose Wegovy; Insmed absorbs ‘expected’ study failure
• Neutral Sentiment: Trading in INSM was briefly halted when the company announced the clinical update, a common market response to material news but not a directional signal by itself. Insmed discontinues development of skin condition drug after mid-stage study miss
• Neutral Sentiment: Billionaire Stan Druckenmiller trimmed his position in Insmed (Duquesne Capital history noted), a disclosure that may reduce some activist/large-holder support but does not reflect current company fundamentals on its own. Insmed Incorporated (INSM): Billionaire Stan Druckenmiller Trims Stake
• Negative Sentiment: Insmed will discontinue development of brensocatib for hidradenitis suppurativa (HS) after the Phase 2b CEDAR study failed to meet primary and secondary endpoints (both 10 mg and 40 mg arms). Management said it will stop the HS program — this removes a potential indication and reduces the drug’s near-term upside. Insmed discontinues development of skin condition drug after mid-stage study miss
• Negative Sentiment: Multiple outlets report the Phase 2b placebo outperformed treatment, prompting program freeze/termination; investors are pricing loss of HS indication and the R&D cost sunk into this program. Insmed’s Brinsupri flops hidradenitis suppurativa study

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.